Virtuals Protocol has introduced private payments for AI agents within its existing Agent Commerce Protocol, enabling AI agents to perform paid tasks and settle transactions on-chain with enhanced privacy. This development adds a privacy layer to the growing ecosystem where companies like Stripe, Tempo, and Visa are building tools for automated payments, identity verification, and transaction coordination for AI agents. The move highlights the expanding role of AI in commerce and the need for secure, private payment systems as software agents increasingly handle financial transactions. Future efforts may focus on licensing content and compensating publishers in automated agent commerce.
Virtuals Protocol's new private payments for AI agents provide context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Oct 20, 2026 01:32 WIB: Among 50 major cryptocurrencies, 41 rose and 8 fell today. EOS led with an 8.13% gain at Rp12.649 and a typical hold time of 87 days, contrasting with CRV's 7.31% rise to Rp6.459 despite a strong sell bias of 99% sell orders. BAT showed a 6.64% increase to Rp3.264 with a balanced order activity near 50%.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
